
10/06/2025
STL startup Wugen has a promising cell treatment for highly deadly forms of leukemia and lymphoma, meeting "a huge unmet medical need."
Wugen has become a standout among St. Louis biotech startups. It has raised more than $300 million in capital since 2018 and employs about 35 people.